Her's another wart. Normally a lot of airplay is given to "over the counter revenue" (as distinct from statutory revenue). I applaud this, as it is clearly more informative. This time deafening silence on OTC revenue. Why?
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game